Design and Evaluation of Bivalent K‐Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202500306 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Naomi Horiuchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Academic Assembly, Institute of Agriculture, Shinshu University, 8304 Minami-Minowa, Kami-Ina, Nagano, 399-4598, Japan. Hauptthemen laut MEDLINE: Alkyl and Aryl Transferases, Farnesyltranstransferase, Enzyme Inhibitors, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Naito Foundation, JSPS, Network Joint Research Center for Materials and Devices (MEXT).
Abstract (Originalsprache)
Mutant K‐Ras drives cancer through its membrane localization, which requires posttranslational modification by farnesyltransferase (FTase). FTase attaches farnesyl to the K‐Ras C‐terminal CVIM tetrapeptide, enabling membrane binding. However, K‐Ras can also undergo compensatory geranylgeranylation by geranylgeranyltransferase I (GGTase I), making FTase inhibition alone ineffective. Dual inhibition of FTase and GGTase I is necessary to fully block K‐Ras localization and its cancer activity. We developed bivalent inhibitors targeting both FTase and GGTase I by binding to the CVIM (C = cysteine, V = valine, I = isoleucine, M = methionine) site and an adjacent acidic surface. A nonthiol CVIM peptidomimetic based on a piperidine scaffold showed potent FTase inhibition ( K i = 2.1 nM) with less effect on GGTase I ( K i = 210 nM). Adding cationic modules to this compound produced dual inhibitors with enhanced potency ( K i = 2–5 nM), significantly improving upon previous agents. These bivalent inhibitors effectively reduced mutant K‐Ras cancer cell viability and inhibited K‐Ras farnesylation and geranylgeranylation in cells. This dual‐targeting approach shows promise for treating K‐Ras‐driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academic Assembly, Institute of Agriculture, Shinshu University, 8304 Minami-Minowa, Kami-Ina, Nagano, 399-4598, Japan.
- Department of Pharmacology and Toxicology, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
- SDMJ Consulting, Gohongi 2-7-8, Meguro, Tokyo, 153-0053, Japan.
- SANKEN, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka, 567-0047, Japan.
ORCID-Profile: Junko Ohkanda
Förderung
- Naito Foundation
- JSPS
- Network Joint Research Center for Materials and Devices (MEXT)
- NCI NIH HHS
- Massey Cancer Center
- NCI-designated Comprehensive Cancer Center
- NIH HHS
- Japan Society for the Promotion of Science
Zitieren
APA
Horiuchi, N., Omer, R., Sugino, F., Ogino, N., Inoue, Y., Aslamuzzaman, K., Suzuki, T., Sebti, S. M., & Ohkanda, J. (2025). Design and Evaluation of Bivalent K‐Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I. Chemistry – A European Journal. https://doi.org/10.1002/chem.202500306
Vancouver
Horiuchi N, Omer R, Sugino F, Ogino N, Inoue Y, Aslamuzzaman K, et al. Design and Evaluation of Bivalent K‐Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I. Chemistry – A European Journal. 2025. doi:10.1002/chem.202500306
BibTeX
@article{Horiuchi2025,
author = {Horiuchi, Naomi and Omer, Rania and Sugino, Fumitoshi and Ogino, Nanami and Inoue, Yoshihisa and Aslamuzzaman, Kazi and Suzuki, Takeyuki and Sebti, Said M and Ohkanda, Junko},
title = {Design and Evaluation of Bivalent K‐Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202500306}
}
EUVIMED